Navigation Links
AG Mednet CEO Abraham Gutman to Moderate Disruptive Technologies Session at CenterWatch Forum on Optimizing Clinical Research Performance
Date:5/14/2013

BOSTON, May 14, 2013 /PRNewswire/ -- On May 19-21 in Boston, clinical trial sponsors, CROs, sites and leaders from around the world will gather at the inaugural CenterWatch Forum on Optimizing Clinical Research Performance conference to discuss collaboration and innovation within a changing clinical trial research landscape.

Among the clinical trial leaders in attendance will be AG Mednet CEO Abraham Gutman who will moderate a special program about successful site leadership and disruptive technologies transforming investigator sites and challenging old assumptions among global networks.

Gutman, recently recognized by CenterWatch as one of 20 innovators changing the face of the clinical trial industry, is responsible for leading AG Mednet and its breakthrough technology that improves the quality of clinical trials by eliminating preventable and costly human errors.

For more information about AG Mednet or to schedule a conversation with Abraham Gutman about the role of disruptive technologies at clinical trial investigative sites around the world, please email agmednet@hbagency.com.

For more information about the Inaugural Forum on Optimizing Clinical Research Performance, please visit http://www.iibig.com/conferences/P1301/overview.html.

About AG Mednet

AG Mednet automates, expedites and improves outcomes in clinical trials by ensuring quality and compliance within critical medical imaging processes. Founded in 2005, AG Mednet is the leading quality compliance partner for image data submission and collection for pharmaceutical, biotechnology and medical device companies, imaging core labs and clinical research organizations managing clinical trials globally. More than 17,000 registered users across thousands of investigator sites in 60 countries use AG Mednet to participate in projects sponsored by each of the world's top 20 pharmaceutical, biotech and medical device companies.

Media Contact: 
Dawn Sullivan or Molly Delaney 
HB Agency 
781-893-0053 
agmednet@hbagency.com


'/>"/>
SOURCE AG Mednet
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AG Mednet Announces Partnership with The Methodist DeBakey Heart & Vascular Center Echocardiography Core Lab
2. AG Mednet and Japans Biovisiq Bring Zero-Delay Clinical Trial Solutions to Asian Pharmaceutical Market
3. MedNet Solutions To Participate In Multiple Clinical Research Conferences In April 2013
4. AG Mednet Announces Cloud Storage Solution with On-Demand Access to Clinical Trial Data
5. MedNet Solutions To Sponsor And Participate In The 2012 SCDM Annual Conference
6. ICON Medical Imaging Selects AG Mednet to Give Clinical Trial Sponsors Zero-Delay Efficiency and Faster Decision-Making Results
7. Prairie Education & Research Cooperative Joins MedNet Solutions iMedNet CRO Partner Program
8. MedNet Solutions to Unveil Innovative New iMedNet EDC Features at The 48th DIA Annual Meeting
9. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
10. Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-Moderate Alzheimers Disease
11. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt University ... first patients in Nashville , Tennesse ... Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. ... to provide long-term reflux control by restoring normal function ... nearly 65 million people in the United ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and ... drug safety and minimize the cost of development. In this webinar, sponsored by ... cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , ...
(Date:4/28/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a ... does not. Yisrayl says with so many titles and names for the Creator, it’s ... with a little Scripture, backed with a lot of research, the truth is undeniable. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec Solutions announced the ... implement a Microsoft Dynamics GP solution that integrates to their PointClickCare EHR software ... in long-term care, Brooke Grove now has the capability to achieve its goal ...
(Date:4/28/2017)... ... ... Rob Lowe is a popular actor that has been in many different ... purpose as the host of the “Informed” series. The program focuses on many important ... series focuses on thyroid cancer. , Although thyroid cancer is an uncommon type of ...
Breaking Medicine News(10 mins):